Abstract Number: 0210 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors
Background/Purpose: Sarilumab is a human IL-6 receptor (IL-6R) inhibitor approved for the treatment of adults with moderate to severely active RA. In the TARGET study…Abstract Number: 0880 • ACR Convergence 2020
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks
Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of…Abstract Number: 1238 • ACR Convergence 2020
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
Background/Purpose: Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderately to severely active RA. The relationship between disease activity,…Abstract Number: 2006 • ACR Convergence 2020
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…Abstract Number: 0226 • ACR Convergence 2020
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
Background/Purpose: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs like methotrexate (MTX) has demonstrated improvement in symptomatic and functional outcomes in patients (pts)…Abstract Number: 0882 • ACR Convergence 2020
Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial
Background/Purpose: Enthesitis is a key feature of all types of spondyloarthritis (SpA) that substantially contributes to the overall burden of disease. Inhibition of the key…Abstract Number: 1329 • ACR Convergence 2020
Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis that can cause remarkable joint damage (1). Subclinical cardiovascular disease (CVD) due to…Abstract Number: 2025 • ACR Convergence 2020
Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
Background/Purpose: Guselkumab (GUS), an interleukin-23 inhibitor, improved axial symptoms of active psoriatic arthritis (PsA) through week 24 in a pooled analysis from two phase 3…Abstract Number: 0232 • ACR Convergence 2020
Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN
Background/Purpose: RA increases a patient’s systemic inflammatory burden, which has been associated with development of chronic kidney disease (CKD), especially in patients with comorbid hypertension,…Abstract Number: 0883 • ACR Convergence 2020
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have demonstrated large clinical improvements in patients with non-radiographic axial spondyloarthritis (nr-axSpA), with patients naïve to bDMARDs experiencing substantial…Abstract Number: 1340 • ACR Convergence 2020
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
Background/Purpose: Patients with non-radiographic axial spondyloarthritis (nr-axSpA) suffer from comparable disease burden to patients with ankylosing spondylitis/radiographic axSpA (AS/r-axSpA), including inflammatory back pain, morning stiffness,…Abstract Number: 2027 • ACR Convergence 2020
Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis.1 The efficacy and safety of TIL up to…Abstract Number: 0240 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures
Background/Purpose: A proportion of adult patients with RA are refractory to TNF inhibitors (TNFi), and treatment with subsequent biologics may be associated with reduced response.…Abstract Number: 0892 • ACR Convergence 2020
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum (ankylosing spondylitis and…Abstract Number: 1352 • ACR Convergence 2020
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…
ACR Meeting Abstracts